NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025, both dates inclusive (the “Class Period”), of the important September 30, 2025 lead plaintiff deadline. SO WHAT: If you purchased Novo Nordisk securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WH ...

In this article, I explain how I have arrived at the decision to sell my shares in Pfizer (NYSE: PFE ) (NEOE: PFE:CA ) and use the proceeds to buy Novo Nordisk (I am a corporate lawyer with an MBA and a long-standing interest in value investing. After spending 7 years practicing at several prestigious Wall Street and Silicon Valley law firms as a corporate transactional lawyer, I founded and have been operating my own boutique law firm for the last 10 years, focusing on investment transactions and the resol ...

I’ve managed my investments since 1999, gaining perspective across multiple market cycles. With a background in Economics from the University of Tartu and ongoing CFA certification, I focus on uncovering deeply undervalued equities with long-term potential often overlooked by the market.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expr ...

I'm an IMC qualified contributor who's followed financial markets for 5 years and has worked professionally in primary investment research for over 2 years. I'm a generalist who enjoys researching businesses from a buttom's up angle with a deep interest in smaller under covered companies where there is greater opportunity for mis-pricing and finding asymmetric opportunities where the downside is limited.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies me ...

公司转型计划 - 宣布全球裁员9000人 占员工总数11% 其中丹麦总部减少5000个岗位[2][3] - 转型旨在简化组织结构 提升决策速度 聚焦糖尿病和肥胖领域增长机会[3] - 预计到2026年底年均节约80亿丹麦克朗（约89.28亿元） 资金将重新投入肥胖症和糖尿病领域商业化及研发[3] - 产生80亿丹麦克朗一次性重组成本 其中第三季度确认90亿丹麦克朗 第四季度节约成本抵消10亿丹麦克朗[4] 业绩预期调整 - 第三次下调2025年营业利润预期 增速从10%-16%下调至4%-10% 降幅达6个百分点[2][8] - 首次下调发生在5月 销售额增速从16%-24%降至13%-21% 营业利润增速从19%-27%降至16%-24%[8] - 第二次下调在7月 销售额增速降至8%-14% 营业利润增速降至10%-16%[8] - 下调原因包括美国市场竞争加剧 司美格鲁肽增长预期降低 及部分市场渗透率不及预期[8] 核心产品表现 - 司美格鲁肽上半年销售额达166.83亿美元 居全球畅销药物之首[2][6] - 减重版Wegovy销售额54.58亿美元 同比增长78% 获FDA批准脂肪肝新适应症[6] - 但第二季度替尔泊肽销售额85.8亿美元 超越司美格鲁肽的84.31亿美元[7] - 中国区销售额近40亿元 但化合物专利2026年到期 已有8家企业提交上市申请[7] 市场竞争态势 - 礼来替尔泊肽上半年销售收入147.34亿美元 成为有史以来爬坡放量最快药物[7] - 司美格鲁肽在美国市场失去领先地位 被礼来超越[7] - GLP-1受体激动剂市场竞争空前激烈 超10款产品处于Ⅱ/Ⅲ期临床试验[7] - 公司承认肥胖症领域竞争日益激烈且消费者需求驱动特征明显[4][6] 历史业绩背景 - 2022年司美格鲁肽销售额109亿美元 带动公司营收同比增长26%[4] - 2023-2024年营收同比增速分别达31%和25%[4] - 快速增长导致组织架构复杂化和运营成本上升[4] - 新任首席执行官迈克·道斯达8月接任后推动转型[4]

当地时间9月10日，总部位于丹麦的生物医药企业诺和诺德公布了一份公司转型计划，其中包括预计 9000人的裁员计划，约为员工总数的11%。与此同时，诺和诺德将2025年营业利润预期下调了6个百分 点，这已经是其年内第三次下调业绩预期。 诺和诺德手握明星药物司美格鲁肽，该药今年上半年销售规模达166.83亿美元，居全球畅销药物之首。 不过，随着更多相同和类似机制药物的上市，司美格鲁肽在全球范围内面临着日益激烈的竞争，这也是 诺和诺德抛出转型计划的初衷之一。 预计裁员9000人 根据声明，诺和诺德的转型计划旨在简化公司组织结构，提升决策速度，并将资源重新聚焦于糖尿病和 肥胖领域的增长机会中。作为转型的一部分，诺和诺德计划在全球78400个岗位中裁减约9000个，照此 计算，裁员比例达11%，其中公司总部所在的丹麦将减少约5000个岗位。 本次裁员涉及公司所有部门，包括职能部门与总部机构，预计到2026年底可年均节约80亿丹麦克朗（约 89.28亿元）。节约的资金将重新投资于肥胖症和糖尿病领域的增长机会中，包括商业化推进措施和研 发项目。转型将立即启动，公司在接下来的几个月时间内将根据各地劳动法的规定，与受影响的员工 ...

据卢特尼克表示，总统特朗普正在调动多个行政部门机构以实现这一目标。"我刚刚接到(卫生部长)博 比·肯尼迪的电话。我还接到了(美国医疗保险和医疗补助服务中心主任)梅赫迈特·奥兹的电话，他们都 和我说，'好吧，让我们开始推进这件事吧'。"卢特尼克在采访中补充说。 总部位于美国的吉利德(GILD.US)、百时美施贵宝(BMY.US)、强生(JNJ.US)、再生元(REGN.US)、安进 (AMGN.US)以及艾伯维(ABBV.US)，还包括总部位于欧洲的大型药企默克集团(Merck KGaA)、赛诺菲 (SNY.US)、葛兰素史克(GSK.US)、阿斯利康(AZN.US)、诺和诺德(NVO.US)、罗氏(RHHBY.US)以及诺 华(NVS.US)也收到了特朗普的来信。 "总统将会说，大型药品制造商们如果不在那边以更高的价格进行出售，就不能在这里销售。别再愿意 以那么低的价格卖给他们了。"卢特尼克在采访中表示。特朗普给药企们设定遵守该最惠国政策的最后 期限为9月29日，并且他在此之前作出了上述的坚定表态。 智通财经APP获悉，美国商务部长霍华德·卢特尼克近日在接受媒体采访时表示，总统唐纳德·特朗普正 在联合多个联邦 ...

Jose Luis Pelaez Inc | Digitalvision | Getty ImagesHealth-care inflation is fueling higher coverage costs, setting the stage for what could be the largest increase in health-care spending by large employers in 15 years.Medical care costs in August rose 4.2% on an annualized basis, according to the Labor Department's Consumer Price Index, compared to an overall inflation rate of 2.9%. The cost of doctors' visits climbed 3.5%, while hospital and outpatient services jumped 5.3%.Those price increases are contri ...

Novo Nordisk will soon require its staff to work in the office full-time after it cut thousands of jobs. The Ozempic maker said it intends to implement a “new global standard” for office-based employees where they will be required to work from the office five days a week. The Danish pharma company’s change in office culture comes just a day after it cut about 11% of its total workforce . Its new policy will go into effect starting Jan.1, it said. “This is designed to foster a stronger sense of belonging ...

Wegovy-maker Novo Nordisk said on Thursday it had told all its staff to return to the office as the drugmaker's new CEO tries to accelerate decision-making and improve its commercial execution amid in... ...